<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719680</url>
  </required_header>
  <id_info>
    <org_study_id>IgPro20_3001</org_study_id>
    <secondary_id>1473</secondary_id>
    <nct_id>NCT00719680</nct_id>
  </id_info>
  <brief_title>Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)</brief_title>
  <official_title>A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (PID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a long-term use of a new human
      immunoglobulin G with proline (IgPro) is safe and effective in the treatment of primary
      immunodeficiency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
    <description>The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population)</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
    <description>The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Any Infection</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
    <description>The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Levels of Total Immunoglobulin G (IgG) Serum Concentrations</measure>
    <time_frame>Before infusion at Weeks 1, 24, 48, 72, and 96</time_frame>
    <description>Mean of individual median total IgG trough concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
    <description>The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Hospitalization Due to Infection</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Hospitalization Due to Infection</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
    <description>The annualized rate was based on the total number of days of hospitalization due to infection and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Antibiotics for Infection Prophylaxis and Treatment</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
    <description>Annualized rate of days with antibiotics for infection prophylaxis and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All AEs by Relatedness and Severity</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
    <description>The rate of AEs was the number of AEs over the number of infusions administered.
At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relatedness and Severity of All AEs (Percentage of Total AEs)</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
    <description>At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Temporally Associated Adverse Event (AE) Within 24 or 72 Hours After an Infusion</measure>
    <time_frame>Within 24 or 72 hours after each infusion</time_frame>
    <description>AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Temporally Associated AEs Within 24 or 72 Hours of an Infusion</measure>
    <time_frame>Within 24 or 72 hours after each infusion</time_frame>
    <description>The rate of AEs was the number of AEs over the number of infusions administered.
AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Mild, Moderate, or Severe Local AEs</measure>
    <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
    <description>In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of infusion site oedema, infusion site reaction, injection site pain, injection site rash, and injection site reaction.
Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs</measure>
    <time_frame>At weeks 1, 12, 24, 36, 48, 60, 72, 84, and 96</time_frame>
    <description>Vital signs included blood pressure (systolic and diastolic), heart rate, and body temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters</measure>
    <time_frame>At Week 1, and study completion (approximately 104 weeks)</time_frame>
    <description>Routine laboratory parameters included hematology, blood chemistry, and urinalysis parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers</measure>
    <time_frame>At Week 1, and study completion (approximately 104 weeks)</time_frame>
    <description>Viral safety markers included human immunodeficiency virus (HIV)-1, HIV-2, hepatitis A virus (HAV), HBV, HCV, and parvovirus B19.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Primary Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>IgPro20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IgPro20</intervention_name>
    <arm_group_label>IgPro20</arm_group_label>
    <other_name>IgG with Proline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with primary humoral immunodeficiency who have participated in the study
             ZLB04_009CR (NCT00419341), namely with a diagnosis of Common Variable Immunodeficiency
             (CVID) as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID
             (European Society for Immunodeficiencies) or X-linked Agammaglobulinemia (XLA) as
             defined by PAGID and ESID

          -  Women of childbearing potential must be using and agree to continue using medically
             approved contraception and must have a negative pregnancy test at screening

          -  Written informed consent

        Exclusion Criteria:

          -  Ongoing serious bacterial infection at the time of screening

          -  Malignancies of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma,
             and immunodeficiency with thymoma

          -  Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined by total
             urine protein concentration &gt; 0.2 g/L)

          -  Other significant medical conditions that could increase the risk to the patient

          -  Females who are pregnant, breast-feeding or planning a pregnancy during the course of
             the study

          -  A positive result at screening on any of the following viral markers: Human
             immunodeficiency virus (HIV), Hepatitis C virus (HCV) or Hepatitis B virus (HBV)

          -  Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) concentration &gt;
             2.5 times Upper Normal Limit (UNL) at Completion Visit of study ZLB04_009CR
             (NCT00419341)

          -  Creatinine concentration &gt; 1.5 times UNL at Completion Visit of study ZLB04_009CR
             (NCT00419341)

          -  Participation in a study with an investigational product other than IgPro20 within 3
             months prior to enrollment

          -  Evidence of uncooperative attitude

          -  Any condition that is likely to interfere with evaluation of the study drug or
             satisfactory conduct of the trial

          -  Subjects who are employees at the investigational site, relatives or spouse of the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Program Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cslbehring.com/clinical-trials/contact-us.htm?registryRefNum=NCT00719680&amp;registryName=ctgov</url>
    <description>Click here to request more information about this study</description>
  </link>
  <results_reference>
    <citation>Jolles S, Borte M, Nelson RP Jr, Rojavin M, Bexon M, Lawo JP, Wasserman RL. Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease. Clin Immunol. 2014 Feb;150(2):161-9. doi: 10.1016/j.clim.2013.10.008. Epub 2013 Oct 26.</citation>
    <PMID>24412910</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2008</study_first_submitted>
  <study_first_submitted_qc>July 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <results_first_submitted>November 27, 2012</results_first_submitted>
  <results_first_submitted_qc>December 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2013</results_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CVID</keyword>
  <keyword>XLA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IgPro20</title>
          <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject’s preference.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IgPro20</title>
          <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject’s preference.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="18.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;= 2 to &lt; 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 12 to &lt; 16 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 16 to &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)</title>
        <description>The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.</description>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The Intention-to-Treat (ITT) population comprised all subjects treated with study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)</title>
          <description>The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.</description>
          <population>The Intention-to-Treat (ITT) population comprised all subjects treated with study medication during any study period.</population>
          <units>infections per subject year</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject Study Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Rate of Any Infection</title>
        <description>The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.</description>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Any Infection</title>
          <description>The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.</description>
          <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
          <units>infections per subject year</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject Study Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Annualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population)</title>
        <description>The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.</description>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The Per-Protocol Efficacy population comprised all subjects who completed at least 48 weeks of the efficacy period that started with the first IgPro20 dose in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population)</title>
          <description>The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.</description>
          <population>The Per-Protocol Efficacy population comprised all subjects who completed at least 48 weeks of the efficacy period that started with the first IgPro20 dose in this study.</population>
          <units>infections per subject year</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject Study Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Levels of Total Immunoglobulin G (IgG) Serum Concentrations</title>
        <description>Mean of individual median total IgG trough concentration.</description>
        <time_frame>Before infusion at Weeks 1, 24, 48, 72, and 96</time_frame>
        <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Levels of Total Immunoglobulin G (IgG) Serum Concentrations</title>
          <description>Mean of individual median total IgG trough concentration.</description>
          <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.98" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection</title>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection</title>
          <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection</title>
        <description>The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.</description>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection</title>
          <description>The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.</description>
          <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
          <units>days per subject year</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject Study Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Hospitalization Due to Infection</title>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Hospitalization Due to Infection</title>
          <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.857" spread="2.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Rate of Hospitalization Due to Infection</title>
        <description>The annualized rate was based on the total number of days of hospitalization due to infection and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.</description>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Hospitalization Due to Infection</title>
          <description>The annualized rate was based on the total number of days of hospitalization due to infection and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.</description>
          <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
          <units>days per subject year</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject Study Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Antibiotics for Infection Prophylaxis and Treatment</title>
        <description>Annualized rate of days with antibiotics for infection prophylaxis and treatment.</description>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Antibiotics for Infection Prophylaxis and Treatment</title>
          <description>Annualized rate of days with antibiotics for infection prophylaxis and treatment.</description>
          <population>The ITT population comprised all subjects treated with study medication during any study period.</population>
          <units>days per subject year</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject Exposure Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.87" lower_limit="5" upper_limit="673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All AEs by Relatedness and Severity</title>
        <description>The rate of AEs was the number of AEs over the number of infusions administered.
At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.</description>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The All-Treated (AT) safety population comprised all subjects treated with the study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All AEs by Relatedness and Severity</title>
          <description>The rate of AEs was the number of AEs over the number of infusions administered.
At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.</description>
          <population>The All-Treated (AT) safety population comprised all subjects treated with the study medication during any study period.</population>
          <units>AEs per infusion</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1735"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relatedness and Severity of All AEs (Percentage of Total AEs)</title>
        <description>At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.</description>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Relatedness and Severity of All AEs (Percentage of Total AEs)</title>
          <description>At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.</description>
          <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
          <units>percentage of total AEs</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>AEs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Temporally Associated Adverse Event (AE) Within 24 or 72 Hours After an Infusion</title>
        <description>AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.</description>
        <time_frame>Within 24 or 72 hours after each infusion</time_frame>
        <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Temporally Associated Adverse Event (AE) Within 24 or 72 Hours After an Infusion</title>
          <description>AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.</description>
          <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs within 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs within 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Temporally Associated AEs Within 24 or 72 Hours of an Infusion</title>
        <description>The rate of AEs was the number of AEs over the number of infusions administered.
AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.</description>
        <time_frame>Within 24 or 72 hours after each infusion</time_frame>
        <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Temporally Associated AEs Within 24 or 72 Hours of an Infusion</title>
          <description>The rate of AEs was the number of AEs over the number of infusions administered.
AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.</description>
          <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
          <units>AEs per infusion</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1735"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs within 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs within 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Mild, Moderate, or Severe Local AEs</title>
        <description>In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of infusion site oedema, infusion site reaction, injection site pain, injection site rash, and injection site reaction.
Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.</description>
        <time_frame>For the duration of the study, up to approximately 104 weeks</time_frame>
        <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Mild, Moderate, or Severe Local AEs</title>
          <description>In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of infusion site oedema, infusion site reaction, injection site pain, injection site rash, and injection site reaction.
Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.</description>
          <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs</title>
        <description>Vital signs included blood pressure (systolic and diastolic), heart rate, and body temperature.</description>
        <time_frame>At weeks 1, 12, 24, 36, 48, 60, 72, 84, and 96</time_frame>
        <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs</title>
          <description>Vital signs included blood pressure (systolic and diastolic), heart rate, and body temperature.</description>
          <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters</title>
        <description>Routine laboratory parameters included hematology, blood chemistry, and urinalysis parameters.</description>
        <time_frame>At Week 1, and study completion (approximately 104 weeks)</time_frame>
        <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters</title>
          <description>Routine laboratory parameters included hematology, blood chemistry, and urinalysis parameters.</description>
          <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers</title>
        <description>Viral safety markers included human immunodeficiency virus (HIV)-1, HIV-2, hepatitis A virus (HAV), HBV, HCV, and parvovirus B19.</description>
        <time_frame>At Week 1, and study completion (approximately 104 weeks)</time_frame>
        <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
        <group_list>
          <group group_id="O1">
            <title>IgPro20</title>
            <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject's preference.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers</title>
          <description>Viral safety markers included human immunodeficiency virus (HIV)-1, HIV-2, hepatitis A virus (HAV), HBV, HCV, and parvovirus B19.</description>
          <population>The AT safety population comprised all subjects treated with the study medication during any study period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of informed consent until study completion, up to approximately 121 weeks</time_frame>
      <desc>The All-Treated (AT) safety population comprised all subjects treated with the study medication during any study period</desc>
      <group_list>
        <group group_id="E1">
          <title>IgPro20</title>
          <description>A liquid formulation of normal human IgG at a concentration of 20%. IgPro20 was administered as a subcutaneous infusion weekly or twice weekly, depending on the investigator's judgment and the subject’s preference.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="248" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Infusion site reaction</sub_title>
                <counts group_id="E1" events="614" subjects_affected="9" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="33" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>CSL agreements may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>CSL Behring</organization>
      <phone>Use email contact</phone>
      <email>clinicaltrials@cslbehring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

